Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Say goodbye to daily insulin shots. NICE has recommended once-weekly insulin efsitora alfa (Onswik) for adults with type 2 diabetes, pending MHRA approval. The weekly jab could cut annual injections from 365 to just 52, with clinical trials showing blood sugar control on par with existing daily basal insulins — and potentially fewer hypoglycaemic episodes.
Say goodbye to daily insulin shots. The UK's National Institute for Health and Care Excellence (NICE) has recommended once-weekly insulin efsitora alfa (Onswik, Eli Lilly) as a treatment option for adults with type 2 diabetes, pending marketing authorisation from the MHRA. The weekly subcutaneous injection — delivered via a pre-filled pen — could reduce annual injections from 365 to just 52, an 85% drop that could meaningfully ease the burden of daily diabetes management.
The recommendation is especially promising for patients who need help administering insulin, such as those who are frail, have learning disabilities, or face challenges with dexterity or vision. For these groups, weekly dosing could also mean fewer carer or healthcare professional visits. NICE noted that overall costs are expected to be similar to or lower than current daily basal insulin regimens, with the biggest savings seen in patients requiring injection assistance. If finalised on September 10, 2026, NHS England must fund the treatment within 90 days.
By the Numbers:
Why it matters: For the millions living with type 2 diabetes — particularly those dependent on carers — a once-weekly insulin option could transform daily life, improve adherence, and reduce healthcare system burden, all without compromising glycaemic control.
